BriaCell Therapeutics (BCTX) said late Wednesday it has completed a public offering of 12 million units at $1.25 each for gross proceeds of $15 million.
BriaCell said it plans to use the proceeds for general business needs, working capital and accelerating its research and development objectives.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.